U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

The Medicines and Healthcare products Regulatory Agency has approved Krystal Biotech’s (KRYS) beremagene geperpavec — Vyjuvek — for the treatment of wounds in patients with dystrophic epidermolysis bullosa. It can be used from birth onward. DEB is a rare genetic condition that makes the skin fragile and prone to blistering due to a fault in a gene responsible for holding skin layers together. Beremagene geperpavec is a gel, applied directly to wounds. In a study of 31 patients aged 1 to 44 years with dystrophic epidermolysis bullosa, beremagene geperpavec was shown to help heal wounds. At 6 months, 67% of wounds treated with the medicine were completely healed, compared with 22% of those treated with placebo.